-
Product Insights
Idiopathic Pulmonary Fibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Idiopathic Pulmonary Fibrosis Clinical Trial Report Overview A total of 713 idiopathic pulmonary fibrosis clinical trials were conducted as of January 2024. The Idiopathic Pulmonary Fibrosis clinical trial report provides a comprehensive understanding of the idiopathic pulmonary fibrosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pulmonary Fibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Pulmonary Fibrosis Clinical Trials Overview The Pulmonary Fibrosis clinical trial report consists of 859 trials. The report provides an overview of the Pulmonary Fibrosis clinical trials scenario. The report provides top-line data relating to the clinical trials on Pulmonary Fibrosis. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Market Report Overview IPF is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). ILDs are characterized by damage to the lung parenchyma (the functional part of the lung that includes the alveolar tissue, bronchioles, bronchi, blood vessels, and interstitium) that occurs as a consequence of aberrant inflammation and fibrosis, thickening and scarring of the connective tissue. The development...